Takeda Pharmaceutical Company Limited
TAK · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $1,113 | $1,107 | $1,053 | $1,144 |
| % Growth | 0.6% | 5.1% | -7.9% | – |
| Cost of Goods Sold | $380 | $385 | $382 | $417 |
| Gross Profit | $733 | $722 | $671 | $727 |
| % Margin | 65.8% | 65.2% | 63.7% | 63.6% |
| R&D Expenses | $161 | $144 | $216 | $170 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $254 | $256 | $296 | $271 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $249 | $138 | $234 | $220 |
| Operating Expenses | $664 | $537 | $746 | $660 |
| Operating Income | $69 | $185 | -$75 | $67 |
| % Margin | 6.2% | 16.7% | -7.1% | 5.9% |
| Other Income/Exp. Net | -$41 | -$34 | -$32 | -$41 |
| Pre-Tax Income | $28 | $151 | -$107 | $26 |
| Tax Expense | $40 | $26 | -$4 | $3 |
| Net Income | -$12 | $124 | -$103 | $24 |
| % Margin | -1.1% | 11.2% | -9.8% | 2.1% |
| EPS | -3.74 | 39.7 | -32.62 | 7.51 |
| % Growth | -109.4% | 221.7% | -534.4% | – |
| EPS Diluted | -3.74 | 39.12 | -32.62 | 7.51 |
| Weighted Avg Shares Out | 3 | 3 | 3 | 3 |
| Weighted Avg Shares Out Dil | 3 | 3 | 3 | 3 |
| Supplemental Information | – | – | – | – |
| Interest Income | $44 | $74 | $0 | $0 |
| Interest Expense | $83 | $107 | $0 | $0 |
| Depreciation & Amortization | $205 | $182 | $190 | $187 |
| EBITDA | $316 | $439 | $181 | $193 |
| % Margin | 28.4% | 39.7% | 17.2% | 16.9% |